<DOC>
	<DOCNO>NCT02060383</DOCNO>
	<brief_summary>The study aim demonstrate pasireotide-induced hyperglycemia effectively safely manage majority patient , include diabetes start pasireotide treatment .</brief_summary>
	<brief_title>Study Management Pasireotide-induced Hyperglycemia Adult Patients With Cushing 's Disease Acromegaly</brief_title>
	<detailed_description>This Phase IV , multi-center , randomize , open-label study . Eligible patient start pasireotide subcutaneously ( s.c. ) Cushing 's disease pasireotide LAR ( long-acting release ) acromegaly . Patients currently treat screen visit pasireotide s.c. LAR eligible long meet protocol criterion screen period . If previously normo-glycemic patient experience increase fast blood glucose meeting criterion diabetes pasireotide , start anti-diabetic treatment use metformin . If continue elevate blood sugar target metformin within first 16 week , randomize 1:1 ratio receive treatment incretin base therapy insulin approximately 16 week .</detailed_description>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Patients great equal 18 year old Confirmed diagnosis Cushing 's disease acromegaly Patients require surgical intervention Patients receive DPP4 inhibitor GLP1 receptor agonist within 4 week prior study entry HbA1c &gt; 10 % screen Known hypersensitivity somatostatin analogues Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cushing 's disease</keyword>
	<keyword>acromegaly</keyword>
	<keyword>pasireotide</keyword>
	<keyword>hyperglycemia</keyword>
</DOC>